70-Gene classifier for differentiation between paclitaxel- and docetaxel-sensitive breast cancers

Cancer Letters

Volumn 314, Issue 2, 2012, Pages 206-212

  Naoi, Y ^a   Tanei, T ^a   Kishi, K ^b   Tsunashima, R ^a   Tominaga, N ^a   Baba, Y ^b   Nakayama, T ^a   Shimazu, K ^a   Kim, S J ^a   Tamaki, Y ^a   Noguchi, S ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b SYSMEX CORPORATION   (Japan)

Author keywords

70 Gene classifier; Breast cancer; DNA microarray; Docetaxel; Paclitaxel

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; KI 67 ANTIGEN; PACLITAXEL; PROGESTERONE RECEPTOR; ANTINEOPLASTIC AGENT; ERBB2 PROTEIN, HUMAN; TAXOID;

70 GENE CLASSIFIER; ADJUVANT THERAPY; ARTICLE; BREAST CANCER; CANCER CLASSIFICATION; CANCER PATIENT; CHEMOSENSITIVITY; CLASSIFIER; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; TREATMENT RESPONSE; BREAST TUMOR; CLASSIFICATION; GENE EXPRESSION PROFILING; GENETICS; PATHOLOGY;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; FEMALE; GENE EXPRESSION PROFILING; HUMANS; KI-67 ANTIGEN; PACLITAXEL; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TAXOIDS;

EID: 84866022786     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.09.032     Document Type: Article

References (38)

1. S.E. Jones, J. Erban, B. Overmoyer, G.T. Budd, L. Hutchins, E. Lower, L. Laufman, S. Sundaram, W.J. Urba, K.I. Pritchard, R. Mennel, D. Richards, S. Olsen, M.L. Meyers, P.M. Ravdin, Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer, J. Clin. Oncol. 23 (2005) 5542-5551.
2. J. Bonneterre, H. Roche, A. Monnier, J.P. Guastalla, M. Namer, P. Fargeot, S. Assadourian, Docetaxel vs 5-fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failure, Br. J. Cancer. 87 (2002) 1210-1215.
3. S. Chan, K. Friedrichs, D. Noel, T. Pinter, S. Van Belle, D. Vorobiof, R. Duarte, M. Gil Gil, I. Bodrogi, E. Murray, L. Yelle, G. von Minckwitz, S. Korec, P. Simmonds, F. Buzzi, R. Gonzalez Mancha, G. Richardson, E. Walpole, M. Ronzoni, M. Murawsky, M. Alakl, A. Riva, J. Crown, Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer, J. Clin. Oncol. 17 (1999) 2341-2354.
4. J.M. Nabholtz, H.J. Senn, W.R. Bezwoda, D. Melnychuk, L. Deschenes, J. Douma, T.A. Vandenberg, B. Rapoport, R. Rosso, V. Trillet-Lenoir, J. Drbal, A. Molino, J.W. Nortier, D.J. Richel, T. Nagykalnai, P. Siedlecki, N. Wilking, J.Y. Genot, P.S. Hupperets, F. Pannuti, D. Skarlos, E.M. Tomiak, M. Murawsky, M. Alakl, M. Aapro, et al., Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy, 304 Study Group, J. Clin. Oncol. 17 (1999) 1413-1424.
5. J. Sjostrom, C. Blomqvist, H. Mouridsen, A. Pluzanska, S. Ottosson-Lonn, N.O. Bengtsson, B. Ostenstad, I. Mjaaland, M. Palm-Sjovall, E. Wist, V. Valvere, H. Anderson, J. Bergh, Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group, Eur. J. Cancer. 35 (1999) 1194-1201.
6. Y.L. Tham, L.F. Gomez, S. Mohsin, M.C. Gutierrez, H. Weiss, S.G. Hilsenbeck, R.M. Elledge, G.C. Chamness, C.K. Osborne, D.C. Allred, J.C. Chang, Clinical response to neoadjuvant docetaxel predicts improved outcome in patients with large locally advanced breast cancers, Breast Cancer Res. Treat. 94 (2005) 279-284.
7. Y. Miyoshi, M. Kurosumi, J. Kurebayashi, N. Matsuura, M. Takahashi, E. Tokunaga, C. Egawa, N. Masuda, S.J. Kim, M. Okishiro, T. Yanagisawa, S. Ueda, T. Taguchi, Y. Tamaki, S. Noguchi, Low nuclear grade but not cell proliferation predictive of pathological complete response to docetaxel in human breast cancers, J. Cancer Res. Clin. Oncol. 134 (2008) 561-567.
8. L.G. Estevez, J.M. Cuevas, A. Anton, J. Florian, J.M. Lopez-Vega, A. Velasco, F. Lobo, A. Herrero, J. Fortes, Weekly docetaxel as neoadjuvant chemotherapy for stage II and III breast cancer: efficacy and correlation with biological markers in a phase II, multicenter study, Clin. Cancer Res. 9 (2003) 686-692.
9. A.D. Seidman, C.A. Hudis, J. Albanell, W. Tong, I. Tepler, V. Currie, M.E. Moynahan, M. Theodoulou, M. Gollub, J. Baselga, L. Norton, Dosedense therapy with weekly 1-h paclitaxel infusions in the treatment of metastatic breast cancer, J. Clin. Oncol. 16 (1998) 3353-3361.
10. E.A. Perez, C.L. Vogel, D.H. Irwin, J.J. Kirshner, R. Patel, Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer, J. Clin. Oncol. 19 (2001) 4216-4223.
11. S. Gori, A.M. Mosconi, C. Basurtol, R. Cherubinil, V. De Angelis, M. Tonato, M. Colozza, Weekly paclitaxel in metastatic breast cancer patients: a phase II study, Tumori 88 (2002) 470-473.
12. K. Sato, K. Inoue, T. Saito, T. Kai, H. Mihara, K. Okubo, J. Koh, H. Mochizuki, T. Tabei, Multicenter phase II trial of weekly paclitaxel for advanced or metastatic breast cancer: the Saitama Breast Cancer Clinical Study Group (SBCCSG-01), Jpn. J. Clin. Oncol. 33 (2003) 371- 376.
13. E.A. Wist, H.H. Sommer, B. Ostenstad, T. Risberg, K. Fjaestad, Weekly 1-h paclitaxel as first-line chemotherapy for metastatic breast cancer, Acta Oncol. 43 (2004) 11-14.
14. A.J. ten Tije, C.H. Smorenburg, C. Seynaeve, A. Sparreboom, K.L. Schothorst, L.G. Kerkhofs, L.G. Van Reisen, G. Stoter, M. Bontenbal, J. Verweij, Weekly paclitaxel as first-line chemotherapy for elderly patients with metastatic breast cancer. A multicentre phase II trial, Eur. J. Cancer 40 (2004) 352-357.
15. D. Lombardi, D. Crivellari, C. Scuderi, M.D. Magri, S. Spazzapan, R. Sorio, V. Di Lauro, S. Scalone, A. Veronesi, Long-term, weekly 1-h infusion of paclitaxel in patients with metastatic breast cancer: a phase II monoinstitutional study, Tumori 90 (2004) 285-288.
16. S. Noguchi, Predictive factors for response to docetaxel in human breast cancers, Cancer Sci. 97 (2006) 813-820.
17. R. Pazdur, A.P. Kudelka, J.J. Kavanagh, P.R. Cohen, M.N. Raber, The taxoids: paclitaxel (Taxol) and docetaxel (Taxotere), Cancer Treat. Rev. 19 (1993) 351-386.
18. J. Gligorov, J.P. Lotz, Preclinical pharmacology of the taxanes: implications of the differences, Oncologist 9 (2004) 3-8.
19. T. Taguchi, T. Aihara, Y. Takatsuka, E. Shin, K. Motomura, H. Inaji, S. Noguchi, Phase II study of weekly paclitaxel for docetaxel-resistant metastatic breast cancer in Japan, Breast J. 10 (2004) 509-513.
20. V. Valero, S.E. Jones, D.D. Von Hoff, D.J. Booser, R.G. Mennel, P.M. Ravdin, F.A. Holmes, Z. Rahman, M.W. Schottstaedt, J.K. Erban, L. Esparza-Guerra, R.H. Earhart, G.N. Hortobagyi, H.A. Burris 3rd, A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer, J. Clin. Oncol. 16 (1998) 3362-3368.
21. T. Tanei, A. Shimomura, K. Shimazu, T. Nakayama, S.J. Kim, T. Iwamoto, Y. Tamaki, S. Noguchi, Prognostic significance of Ki67 index after neoadjuvant chemotherapy in breast cancer, Eur. J. Surg. Oncol. 37 (2011) 155-161.
22. M.C. Green, A.U. Buzdar, T. Smith, N.K. Ibrahim, V. Valero, M.F. Rosales, M. Cristofanilli, D.J. Booser, L. Pusztai, E. Rivera, R.L. Theriault, C. Carter, D. Frye, K.K. Hunt, W.F. Symmans, E.A. Strom, A.A. Sahin, W. Sikov, G.N. Hortobagyi, Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks, J. Clin. Oncol. 23 (2005) 5983-5992.
23. Y. Naoi, K. Kishi, T. Tanei, R. Tsunashima, N. Tominaga, Y. Baba, S.J. Kim, T. Taguchi, Y. Tamaki, S. Noguchi, Prediction of pathologic complete response to sequential paclitaxel and 5-fluorouracil/epirubicin/cyclophosphamide therapy using a 70-gene classifier for breast cancers, Cancer 117 (2011) 3682-3690.
24. S.J. Kim, T. Taguchi, K. Shimazu, Y. Tanji, Y. Tamaki, S. Noguchi, Good response to paclitaxel predicts high rates of pathologic complete response for breast cancer patients treated preoperatively with paclitaxel followed by 5-fluorouracil, epirubicin and cyclophosphamide, Oncology 77 (2009) 134-139.
25. K. Morimoto, S.J. Kim, T. Tanei, K. Shimazu, Y. Tanji, T. Taguchi, Y. Tamaki, N. Terada, S. Noguchi, Stem cell marker aldehyde dehydrogenase 1-positive breast cancers are characterized by negative estrogen receptor, positive human epidermal growth factor receptor type 2, and high Ki67 expression, Cancer Sci. 100 (2009) 1062-1068.
26. C.W. Elston, I.O. Ellis, Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up, Histopathology 19 (1991) 403-410.
27. D.F. Hayes, A.D. Thor, L.G. Dressler, D. Weaver, S. Edgerton, D. Cowan, G. Broadwater, L.J. Goldstein, S. Martino, J.N. Ingle, I.C. Henderson, L. Norton, E.P. Winer, C.A. Hudis, M.J. Ellis, D.A. Berry, HER2 and response to paclitaxel in node-positive breast cancer, N. Engl. J. Med. 357 (2007) 1496-1506.
28. F. Penault-Llorca, C. Abrial, I. Raoelfils, P. Chollet, A. Cayre, M.A. Mouret-Reynier, E. Thivat, F. Mishellany, P. Gimbergues, X. Durando, Changes and predictive and prognostic value of the mitotic index, Ki-67, cyclin D1, and cyclo-oxygenase-2 in 710 operable breast cancer patients treated with neoadjuvant chemotherapy, Oncologist 13 (2008) 1235-1245.
29. R.L. Jones, J. Salter, R. A'Hern, A. Nerurkar, M. Parton, J.S. Reis-Filho, I.E. Smith, M. Dowsett, Relationship between oestrogen receptor status and proliferation in predicting response and long-term outcome to neoadjuvant chemotherapy for breast cancer, Breast Cancer Res. Treat. 119 (2010) 315-323.
30. G. MacGrogan, L. Mauriac, M. Durand, F. Bonichon, M. Trojani, I. de Mascarel, J.M. Coindre, Primary chemotherapy in breast invasive carcinoma: predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erbB-2, MiB1, pS2 and GST pi, Br. J. Cancer. 74 (1996) 1458-1465.
31. T. Petit, M. Wilt, M. Velten, R. Millon, J.F. Rodier, C. Borel, R. Mors, P. Haegele, M. Eber, J.P. Ghnassia, Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy, Eur. J. Cancer. 40 (2004) 205-211.
32. C. Bozzetti, A. Musolino, R. Camisa, G. Bisagni, M. Flora, C. Bassano, E. Martella, C. Lagrasta, R. Nizzoli, N. Personeni, F. Leonardi, G. Cocconi, A. Ardizzoni, Evaluation of HER-2/neu amplification and other biological markers as predictors of response to neoadjuvant anthracycline-based chemotherapy in primary breast cancer: the role of anthracycline dose intensity, Am. J. Clin. Oncol. 29 (2006) 171-177.
33. I.F. Faneyte, P.M. Kristel, M.J. Van de Vijver, Multidrug resistance associated genes MRP1, MRP2 and MRP3 in primary and anthracycline exposed breast cancer, Anticancer Res. 24 (2004) 2931-2939.
34. M. Colleoni, G. Viale, D. Zahrieh, L. Bottiglieri, R.D. Gelber, P. Veronesi, A. Balduzzi, R. Torrisi, A. Luini, M. Intra, S. Dellapasqua, A. Cardillo, R. Ghisini, G. Peruzzotti, A. Goldhirsch, Expression of ER, PgR, HER1, HER2, and response: a study of preoperative chemotherapy, Ann. Oncol. 19 (2008) 465-472.
35. M. Martin, A. Romero, M.C. Cheang, J.A. Lopez Garcia-Asenjo, J.A. Garcia-Saenz, B. Oliva, J.M. Roman, X. He, A. Casado, J. de la Torre, V. Furio, J. Puente, T. Caldes, J.A. Vidart, S. Lopez-Tarruella, E. Diaz-Rubio, C.M. Perou, Genomic predictors of response to doxorubicin versus docetaxel in primary breast cancer, Breast Cancer Res. Treat. 128 (2011) 127-136.
36. J. Sjostrom, C. Blomqvist, P. Heikkila, K.V. Boguslawski, A. Raisanen-Sokolowski, N.O. Bengtsson, I. Mjaaland, P. Malmstrom, B. Ostenstadt, J. Bergh, E. Wist, V. Valvere, E. Saksela, Predictive value of p53, mdm-2, p21, and mib-1 for chemotherapy response in advanced breast cancer, Clin. Cancer Res. 6 (2000) 3103-3110.
37. J.C. Chang, E.C. Wooten, A. Tsimelzon, S.G. Hilsenbeck, M.C. Gutierrez, R. Elledge, S. Mohsin, C.K. Osborne, G.C. Chamness, D.C. Allred, P. O'Connell, Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer, Lancet 362 (2003) 362-369.
38. K. Iwao-Koizumi, R. Matoba, N. Ueno, S.J. Kim, A. Ando, Y. Miyoshi, E. Maeda, S. Noguchi, K. Kato, Prediction of docetaxel response in human breast cancer by gene expression profiling, J. Clin. Oncol. 23 (2005) 422-431.